文献速递核素与放射性配体治疗肿瘤 PET/CT

放射性药物治疗相关肿瘤耐药:免疫逃逸、非免疫机制与免疫代谢脆弱性

Radiopharmaceutical Therapy-Linked Tumor Resistance: Immune Evasion, Nonimmune Mechanisms, and Immunometabolic Vulnerabilities.
PubMed 文献 · J Nucl Med · 2026-09-11

本文综述放射性药物治疗(RPT)在转移性去势抵抗性前列腺癌和神经内分泌肿瘤等中的耐药机制,涵盖肿瘤细胞内在信号、肿瘤免疫微环境与肿瘤代谢,并总结克服耐药的策略及先进临床前模型进展,重点以前列腺癌为例。

要点

  • RPT耐药涉及肿瘤细胞内在信号、免疫微环境与代谢三类机制。
  • 克服RPT耐药需开发联合策略以实现更持久应答。
  • 先进临床前模型对验证RPT联合方案至关重要。

核心结论

  • RPT后复发跨癌种出现,亟需新策略克服耐药以实现更持久应答。

研究设计与样本

  • 综述,总结RPT耐药机制(肿瘤细胞内在信号、肿瘤免疫微环境、肿瘤代谢)及克服策略与先进临床前模型进展。

主要发现

  • RPT耐药机制涉及肿瘤细胞内在信号、肿瘤免疫微环境和肿瘤代谢。
  • 先进临床前模型能更好再现人类代谢与免疫应答,对验证联合方案至关重要。

临床怎么用

  • 可依据肿瘤细胞内在信号、免疫微环境和代谢三类机制设计RPT联合策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiopharmaceutical therapy (RPT) has transformed the management of metastatic castration-resistant prostate cancer and neuroendocrine tumors, with clinical development extending to renal cell carcinoma, hepatocellular carcinoma, lung cancer, and breast cancer. Because relapse after RPT occurs across cancer types, there is an urgent need to implement new treatment strategies to overcome resistance and achieve more durable responses. Here, we summarize recent advances in research concerning RPT resistance mechanisms involving tumor cell-intrinsic signaling, the tumor immune microenvironment, and tumor metabolism, as well as emerging strategies to overcome them. We also highlight progress in advanced preclinical models that better recapitulate human metabolism and immune responses, which are essential for validating new combination approaches designed to maximize the clinical benefit of RPT, with a focus on prostate cancer.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Abt ER, Radu CG, Czernin J, et al. Radiopharmaceutical Therapy-Linked Tumor Resistance: Immune Evasion, Nonimmune Mechanisms, and Immunometabolic Vulnerabilities. J Nucl Med. 2026. PMID: 42728104. doi:10.2967/jnumed.125.269489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。